Petros pharmaceuticals expands program for novel investigational non-invasive treatment formulation for peyronie's disease

New york, nov. 8, 2021 /prnewswire/ -- petros pharmaceuticals, inc. (nasdaq: ptpi), a leading provider of therapeutics for men's health, announces today the expansion of its program for investigational h100, a novel patented non-invasive topical treatment under development for peyronie's disease. h100 is a topical gel formulated to address the inflammatory cascade that leads to pain, scarring and penile irregularities associated with peyronie's disease.
PTPI Ratings Summary
PTPI Quant Ranking